Literature DB >> 639229

Reduction of enzyme levels by propranolol after acute myocardial infarction.

T Peter, R M Norris, E D Clarke, M K Heng, B N Singh, B Williams, D R Howell, P K Ambler.   

Abstract

The effect of propranolol (0.1 mg/kg intravenously followed by 320 mg given over 27 hour orally) on serum levels of creatine kinase enzyme was studied in a randomized trial involving 95 patients seen within 12 hours of onset of symptoms of uncomplicated myocardial infarction. In 15 patients who were treated with propranolol within 4 hours of onset, and who eventually developed pathological Q waves, peak measured enzyme levels were 27% (P less than 0.0125) lower than in 19 control patients who were also seen within 4 hours of the onset but had no specific treatment. Total calculated enzyme appearance was also lower in the treated patients (reduced 25%, P less than 0.05) as was the calculated rate of the appearance (33%, P less than 0.005). No significant difference was found for treated compared with control patients entering the trial more than 4 hours after the onset of chest pain. This evidence suggests that propranolol may reduce the size of uncomplicated infarctions if it is given intravenously within 4 hours of the onset.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 639229     DOI: 10.1161/01.cir.57.6.1091

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  32 in total

Review 1.  According to MIAMI and ISIS-I trials, can a general recommendation be given for beta blockers in acute myocardial infarction?

Authors:  J K Kjekshus
Journal:  Cardiovasc Drugs Ther       Date:  1988-05       Impact factor: 3.727

2.  Early intravenous beta-blockers in patients with acute coronary syndrome--a meta-analysis of randomized trials.

Authors:  Saurav Chatterjee; Debanik Chaudhuri; Rajesh Vedanthan; Valentin Fuster; Borja Ibanez; Sripal Bangalore; Debabrata Mukherjee
Journal:  Int J Cardiol       Date:  2012-11-17       Impact factor: 4.164

Review 3.  Cardiogenic shock.

Authors:  C E Handler
Journal:  Postgrad Med J       Date:  1985-08       Impact factor: 2.401

4.  Limitation of myocardial infarct size. Present status.

Authors:  S Yusuf; P Sleight
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

Review 5.  The potential for added benefits with beta-blockers and calcium antagonists in treating cardiovascular disorders.

Authors:  W G Nayler
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  Beta-adrenoceptor blockers. An update on their role in acute myocardial infarction.

Authors:  R M Norris
Journal:  Drugs       Date:  1985-02       Impact factor: 9.546

7.  Effect of early treatment with propranolol on left ventricular function four weeks after myocardial infarction.

Authors:  M A Brown; R M Norris; P F Barnaby; G G Geary; P W Brandt
Journal:  Br Heart J       Date:  1985-10

8.  Development of congestive heart failure after treatment with metoprolol in acute myocardial infarction.

Authors:  J Herlitz; A Hjalmarson; S Holmberg; K Swedberg; A Vedin; F Waagstein; A Waldenström; H Wedel; L Wilhelmsen; C Wilhelmsson
Journal:  Br Heart J       Date:  1984-05

9.  Metabolic and haemodynamic effects of increased circulating adrenaline in man. Effect of labetalol, an alpha and beta blocker.

Authors:  A D Struthers; R Whitesmith; J L Reid
Journal:  Br Heart J       Date:  1983-09

10.  Role of labetalol in acute myocardial infarction.

Authors:  A D Timmis; M B Fowler; N S Jaggarao; R Vincent; D A Chamberlain
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.